Promomed Group of Companies has registered the anticoagulant Enoparin

Promomed Group's portfolio of medicines, which are in demand to combat the new coronavirus infection and its complications, has been replenished with a new drug, Enoparin (Sodium Enoxaparin).

On August 13, 2021, the Ministry of Health of the Russian Federation issued a registration certificate for a solution for injection of Enoparin (enoxaparin sodium) in various dosages.

"Already in the first months of the pandemic, Promomed developed and released the direct-acting antiviral agent Areplivir. Since then, we have been systematically and intensively working to expand the anti-covid portfolio, conduct relevant research and develop the production base. As the new virus is studied, its effects on the body, as well as complications and long-term health consequences, the range of Promomed drugs in demand to combat the disease is also expanding. Today, it includes medicines for the treatment of covid-19 itself, modern antibiotics, some other drugs, and now the effective anticoagulant Enoparin," commented Peter Bely, Chairman of the Board of Directors of Promomed Group.

The manufacturer of the finished dosage form and substance for the drug "ENOPARIN" is the Biochemist plant, which is part of Promomed Group of Companies. The main active ingredient— sodium enoxaparin, is isolated from the raw materials of low molecular weight heparins by modern biotechnological methods of purification and sterilization.

In the near future, Promomed, in partnership with the Mendeleev Engineering Center, will complete the development and introduction into production of a technology for producing low-molecular-weight heparins from raw materials of domestic origin, which will ensure full localization of the drug's production in Russia.

Enoxaparin sodium is an effective anticoagulant recommended by the Ministry of Health of the Russian Federation to prevent a common complication of coronavirus infection — thrombosis and thromboembolism. It is used for the prevention and treatment of deep vein thrombosis, prevention of ischemic complications of unstable angina and myocardial infarction.